Elanco Animal Health (NYSE:ELAN) Announces Quarterly Earnings Results

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.08, Briefing.com reports. The business had revenue of $1.21 billion for the quarter, compared to analysts' expectations of $1.18 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The company's revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.45 EPS.

Elanco Animal Health Stock Up 1.9 %

Shares of ELAN stock traded up $0.31 during trading on Thursday, reaching $17.21. The company's stock had a trading volume of 7,407,675 shares, compared to its average volume of 4,585,274. The stock's 50-day moving average price is $14.98 and its 200 day moving average price is $14.04. The company has a market capitalization of $8.50 billion, a price-to-earnings ratio of -6.79, a P/E/G ratio of 1.42 and a beta of 1.34. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. Elanco Animal Health has a 1-year low of $7.88 and a 1-year high of $17.43.

Insiders Place Their Bets

In other Elanco Animal Health news, Director R David Hoover bought 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the purchase, the director now directly owns 185,000 shares in the company, valued at $2,985,900. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on ELAN. Morgan Stanley raised their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, February 27th. Barclays lifted their price objective on shares of Elanco Animal Health from $19.00 to $23.00 and gave the company an "overweight" rating in a report on Thursday. The Goldman Sachs Group upped their price objective on Elanco Animal Health from $12.50 to $14.00 and gave the stock a "sell" rating in a research note on Tuesday, February 27th. Finally, TheStreet upgraded shares of Elanco Animal Health from a "d+" rating to a "c-" rating in a research note on Friday, February 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.29.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.